Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth ConferencePRNewsWire • 08/13/20
Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye DiseasePRNewsWire • 08/05/20
Palatin's stock rises on plans to test experimental drug as COVID-19 treatmentMarket Watch • 06/23/20
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2020 - Earnings Call TranscriptSeeking Alpha • 02/11/20
Palatin Technologies' (PTN) CEO Carl Spana on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/13/19
Palatin Technologies: Vyleesi Growth Potential And Milestone Payments Should Lift Share PricesSeeking Alpha • 10/28/19
Palatin Technologies, Inc. (PTN) CEO Dr. Carl Spana on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 09/12/19
Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 08/06/19
Palatin's stock rockets after FDA OK to market sexual desire disorder treatmentMarket Watch • 06/24/19
Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/09/19